GlassScriptPhysician profile
Francisco A Ward
NPI 1245225226
$3,631.12
in general payments reported to CMS, 2019-2025
32 companies · $21.25 in 2025
The $21.25 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $138 · 2021: $1,024 · 2022: $842 · 2023: $673 · 2024: $770 · 2025: $21.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388 · Entertainment: $60.02 · Travel and Lodging: $15.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.35 |
| Entertainment | $60.02 |
| Travel and Lodging | $15.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $614.27 | 2021 | |
| Abbvie INC. | $309.46 | 2021-2024 | Ubrelvy |
| Foundation Fusion Solutions, LLC | $294.25 | 2024 | |
| Grt US Holding, INC. | $290.22 | 2021-2022 | |
| Boston Scientific Corporation | $266.64 | 2020-2023 | Infinion 16, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $216.82 | 2019-2022 | |
| Medtronic, INC. | $213.92 | 2023 | Intellis Adaptivestim |
| Spinal Simplicity, LLC | $196.91 | 2022 | |
| Biotronik Nro, INC. | $196.49 | 2023-2024 | Prospera, Biotronik |
| Protega Pharmaceutials INC | $146.77 | 2023-2024 | Roxybond |
| Amgen INC. | $124.16 | 2019 | |
| Collegium Pharmaceutical, INC. | $123.75 | 2020-2024 | Xtampza, Belbuca |
| Angiodynamics, INC. | $76.50 | 2021 | |
| Depuy Synthes Sales INC. | $63.89 | 2022-2024 | Orthovisc |
| Nevro Corp. | $58.28 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $49.47 | 2024-2025 | |
| Electronic Waveform Lab, INC. | $49.38 | 2024 | |
| Novartis Pharmaceuticals Corporation | $42.18 | 2019-2020 | |
| Almatica Pharma LLC | $41.96 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.69 | 2022 | |
| Vertos Medical, INC. | $30.21 | 2024 | Mild Device Kit |
| Painteq LLC | $24.04 | 2024 | Painteq |
| Saluda Medical Americas, INC. | $24.03 | 2024 | Evoke |
| Averitas Pharma INC. | $21.30 | 2023 | Qutenza |
| Pfizer INC. | $18.95 | 2024 | |
| Scilex Pharmaceuticals INC. | $17.15 | 2020 | |
| Pacira Therapeutics, INC. | $16.26 | 2021 | |
| Flowonix Medical Incorporated | $15.25 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.25 | 2022 | |
| Fidia Pharma USA INC. | $13.47 | 2021 | |
| Metacel Pharmaceuticals LLC | $13.34 | 2022 | |
| Biodelivery Sciences International, INC. | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisco Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.